Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23416656 | 0.88 | — | — | |
| SCHEMBL23416709 | 0.88 | AVPR1A (0.33) | AVPR1A | |
| SCHEMBL23416655 | 0.78 | NOTUM (0.31) | — | |
| SCHEMBL23416646 | 0.75 | — | — | |
| SCHEMBL22993440 | 0.71 | KDM4E (0.31) | — | |
| SCHEMBL23416644 | 0.68 | CCR1 (0.31) | — | |
| SCHEMBL23416642 | 0.65 | GAA (0.35) | — | |
| SCHEMBL23416684 | 0.65 | — | — | |
| SCHEMBL23416685 | 0.65 | CHRM4 (0.31) | — | |
| SCHEMBL7914448 | 0.64 | CCR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339177-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-05-24 | — | — | US | disclosed |
| EP-3642193-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS AND RELATED COMPOSITION | ZHANG XIAOHU (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20210155635-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339177-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same | BAX, LITAF, PNLIP | AVPR1A 4837/4885 |
| US-20210155635-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME | BAX, LITAF, PNLIP | AVPR1A 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.